Literature DB >> 25684686

Bombesin staining in neuroendocrine cell hyperplasia of infancy (NEHI) and other childhood interstitial lung diseases (chILD).

Slaveya G Yancheva1, Asha Velani1, Alexandra Rice1,2, Angeles Montero1,2, David M Hansell2,3, Sergio Koo4, Lina Thia5, Andrew Bush2,4, Andrew G Nicholson1,2.   

Abstract

AIMS: We have analysed levels of bombesin-positive neuroendocrine cells (NECs) in neuroendocrine cell hyperplasia of infancy (NEHI) and other childhood interstitial lung diseases (chILDs) in order to validate proposed histological criteria for NEHI and investigate its aetiology. METHODS AND
RESULTS: The extent of bombesin-positive cells within airway epithelium was analysed in lung biopsies from seven patients diagnosed with NEHI, including two classified previously as non-diagnostic, and other chILDs (n = 64) with age ranges of 1 month-18 years. NECs were counted and calculated as a percentage of airways containing NECs, average percentage of NECs per airway, percentage of airways with >10% NECs and number of neuroendocrine bodies (NEBs). Correlation with age and gender was also undertaken. Patients with NEHI had the highest average percentage of bombesin-positive NECs per airway compared to other chILDs. However, NEH was also seen in many other chILDs, and appears to be most prominent in disorders associated with lung immaturity such as histological patterns associated with surfactant protein-related disorders and pulmonary interstitial glycogenosis.
CONCLUSIONS: NEH may, to a degree, be a marker of airway immaturity rather than the direct cause of NEHI. This possibility is supported by the fact that the number of bombesin-positive NECs decreased with age in this cohort, independent of disease type. The average percentage of bombesin-positive NECs per airway appears to be the best histological criterion for assessing the extent of NECs in the context of NEHI.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  bombesin; children; interstitial lung disease; lung; neuroendocrine cell hyperplasia of infancy

Mesh:

Substances:

Year:  2015        PMID: 25684686     DOI: 10.1111/his.12672

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

1.  A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome.

Authors:  Lea Maria Merz; Florian Buerger; Niels Ziegelasch; Martin Zenker; Ilse Wieland; Tobias Lipek; Tillmann Wallborn; Nicolas Terliesner; Freerk Prenzel; Manuela Siekmeyer; Katalin Dittrich
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-06       Impact factor: 6.055

Review 2.  Update on Diffuse Lung Disease in Children.

Authors:  Timothy J Vece; Lisa R Young
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

3.  Pulmonary Neuroendocrine Cell Hyperplasia Associated with Surfactant Protein C Gene Mutation.

Authors:  Norlalak Jiramethee; David Erasmus; Lawrence Nogee; Andras Khoor
Journal:  Case Rep Pulmonol       Date:  2017-11-09

4.  Role of High-Resolution Chest Computed Tomography in a Child with Persistent Tachypnoea and Intercostal Retractions: A Case Report of Neuroendocrine Cell Hyperplasia.

Authors:  Mara Lelii; Maria Francesca Patria; Raffaella Pinzani; Rossana Tenconi; Alessandro Mori; Nicola Bonelli; Nicola Principi; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2017-09-25       Impact factor: 3.390

5.  Case report: Rare lung disease of infancy diagnosed with the assistance of a home pulse oximetry baby monitor.

Authors:  Kevin H Yang; Art Kulatti; Kimberly Sherer; Aparna Rao; Mateja Cernelc-Kohan
Journal:  Front Pediatr       Date:  2022-09-06       Impact factor: 3.569

6.  Neuroendocrine cell hyperplasia of infancy: an unusual cause of hypoxemia in children.

Authors:  Silvia Caimmi; Amelia Licari; Davide Caimmi; Anna Rispoli; Eugenio Baraldi; Fiorella Calabrese; Gian Luigi Marseglia
Journal:  Ital J Pediatr       Date:  2016-09-15       Impact factor: 2.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.